APYX
Income statement / Annual
Last year (2023), Apyx Medical Corporation's total revenue was $52.35 M,
an increase of 17.61% from the previous year.
In 2023, Apyx Medical Corporation's net income was -$18.71 M.
See Apyx Medical Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$52.35 M
|
$44.51 M
|
$48.52 M
|
$27.71 M
|
$28.15 M
|
$16.69 M
|
$38.88 M
|
$36.63 M
|
$29.52 M
|
$27.68 M
|
| Cost of Revenue |
$18.59 M |
$15.38 M |
$14.92 M |
$10.21 M |
$9.03 M |
$5.89 M |
$19.12 M |
$18.71 M |
$16.96 M |
$18.69 M |
| Gross Profit |
$33.76 M |
$29.13 M |
$33.60 M |
$17.50 M |
$19.13 M |
$10.79 M |
$19.76 M |
$17.92 M |
$12.56 M |
$8.99 M |
| Gross Profit Ratio |
0.64 |
0.65 |
0.69 |
0.63 |
0.68 |
0.65 |
0.51 |
0.49 |
0.43 |
0.32 |
| Research and Development
Expenses |
$4.84 M
|
$4.54 M
|
$4.32 M
|
$3.92 M
|
$3.81 M
|
$2.47 M
|
$2.46 M
|
$2.62 M
|
$2.16 M
|
$1.42 M
|
| General & Administrative
Expenses |
$48.87 M
|
$48.15 M
|
$43.73 M
|
$33.67 M
|
$36.23 M
|
$21.18 M
|
$21.05 M
|
$19.09 M
|
$17.38 M
|
$13.43 M
|
| Selling & Marketing
Expenses |
$0.00
|
$2.30 M
|
$1.30 M
|
$800,000.00
|
$1.50 M
|
$800,000.00
|
$11.37 M
|
$8.57 M
|
$8.42 M
|
$6.69 M
|
| Selling, General &
Administrative Expenses |
$48.87 M
|
$48.15 M
|
$43.73 M
|
$33.67 M
|
$36.23 M
|
$21.18 M
|
$21.05 M
|
$19.09 M
|
$17.38 M
|
$13.43 M
|
| Other Expenses |
$0.00 |
$509,000.00 |
-$373,000.00 |
$479,000.00 |
-$382,000.00 |
-$203,000.00 |
-$11.37 M |
-$8.57 M |
-$8.42 M |
-$6.69 M |
| Operating Expenses |
$51.02 M |
$52.69 M |
$48.05 M |
$37.59 M |
$40.04 M |
$23.65 M |
$23.50 M |
$21.71 M |
$19.54 M |
$14.84 M |
| Cost And Expenses |
$69.61 M |
$68.07 M |
$62.97 M |
$47.79 M |
$49.07 M |
$29.55 M |
$42.62 M |
$40.42 M |
$36.51 M |
$33.53 M |
| Interest Income |
$921,000.00 |
$157,000.00 |
$11,000.00 |
$241,000.00 |
$1.39 M |
$616,000.00 |
$0.00 |
$0.00 |
$1,000.00 |
$0.00 |
| Interest Expense |
$2.48 M |
$15,000.00 |
$10,000.00 |
$46,000.00 |
$8,000.00 |
$104,000.00 |
$136,000.00 |
$158,000.00 |
$158,000.00 |
$151,000.00 |
| Depreciation &
Amortization |
$692,000.00
|
$890,000.00
|
$903,000.00
|
$887,000.00
|
$754,000.00
|
$669,000.00
|
$696,000.00
|
$734,000.00
|
$812,000.00
|
$876,000.00
|
| EBITDA |
-$18.11 M
|
-$22.01 M
|
-$13.91 M
|
-$18.48 M
|
-$19.07 M
|
-$13.92 M
|
-$13.01 M
|
-$3.79 M
|
-$4.37 M
|
-$12.25 M
|
| EBITDA Ratio |
-0.35 |
-0.51 |
-0.31 |
-0.7 |
-0.71 |
-0.78 |
-0.1 |
-0.1 |
-0.24 |
-0.21 |
| Operating Income Ratio
|
-0.33
|
-0.53
|
-0.3
|
-0.72
|
-0.74
|
-0.82
|
-0.14
|
-0.1
|
-0.24
|
-0.21
|
| Total Other
Income/Expenses Net |
-$4.02 M
|
$651,000.00
|
-$372,000.00
|
$674,000.00
|
$1.03 M
|
-$1.09 M
|
-$8.57 M
|
-$94,000.00
|
$1.64 M
|
-$7.44 M
|
| Income Before Tax |
-$21.28 M |
-$22.91 M |
-$14.82 M |
-$19.41 M |
-$19.91 M |
-$13.27 M |
-$5.22 M |
-$3.89 M |
-$5.35 M |
-$13.29 M |
| Income Before Tax Ratio
|
-0.41
|
-0.51
|
-0.31
|
-0.7
|
-0.71
|
-0.8
|
-0.13
|
-0.11
|
-0.18
|
-0.48
|
| Income Tax Expense |
-$2.43 M |
$367,000.00 |
$380,000.00 |
-$7.50 M |
-$260,000.00 |
-$3.78 M |
-$156,000.00 |
$64,000.00 |
$25,000.00 |
$4.00 M |
| Net Income |
-$18.71 M |
-$23.28 M |
-$15.20 M |
-$11.91 M |
-$19.65 M |
$64.01 M |
-$5.06 M |
-$3.95 M |
-$5.37 M |
-$17.28 M |
| Net Income Ratio |
-0.36 |
-0.52 |
-0.31 |
-0.43 |
-0.7 |
3.84 |
-0.13 |
-0.11 |
-0.18 |
-0.62 |
| EPS |
-0.54 |
-0.67 |
-0.44 |
-0.35 |
-0.58 |
1.93 |
-0.16 |
-0.14 |
-0.22 |
-0.98 |
| EPS Diluted |
-0.54 |
-0.67 |
-0.44 |
-0.35 |
-0.58 |
1.86 |
-0.16 |
-0.14 |
-0.19 |
-0.97 |
| Weighted Average Shares
Out |
$34.62 M
|
$34.52 M
|
$34.33 M
|
$34.21 M
|
$34.07 M
|
$33.19 M
|
$31.42 M
|
$27.43 M
|
$24.33 M
|
$17.68 M
|
| Weighted Average Shares
Out Diluted |
$34.62 M
|
$34.52 M
|
$34.33 M
|
$34.21 M
|
$34.07 M
|
$34.37 M
|
$31.43 M
|
$27.45 M
|
$27.75 M
|
$17.76 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
